臨床試驗
The first line treatment option for women with HMB and no identified pathology, fibroids less than 3 cm in diameter, suspected or confirmed adenomyosis is the levonorgestrel-releasing intrauterine system (LNG-IUS). Clinical trial evidence suggests that the LNG-IUS may be better than other medical therapy in terms of HMB and quality of life.